Cell line · CVCL_1619
OCI-AML-2
Cancer cell line, Homo sapiens. Adult acute myeloid leukemia. 39 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. OCI-AML-2. Cell lines, record CVCL_1619. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1619
On this page
Cell line
As Cellosaurus gives it.
- Name
- OCI-AML-2
- Accession
- CVCL_1619
- RRID
- RRID:CVCL_1619
- Synonyms
- OCI/AML-2, OCIAML-2, OCI-AML2, OCI/AML2, OCI AML2, OCIAML2, AML-2, Ontario Cancer Institute-Acute Myeloid Leukemia-2
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 65Y
- Category
- Cancer cell line
- Diseases
- Adult acute myeloid leukemia (NCIt C9154); Acute myeloid leukemia with t(6;11)(q27;q23) KMT2A-MLLT4 (NCIt C132105); Acute myeloid leukemia (ORDO Orphanet_519)
- Derived from
- Peripheral blood (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers39
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting SMC3 deacetylation synergizes with XPO1 inhibition to reprogram the epigenetic landscape and suppress NPM1-mutated acute myeloid leukemia. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cysteine-reactive covalent chloro-N-acetamide ligands induce ferroptosis mediated cell death. | EMBO Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. | Mol Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). | Blood Cancer J | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 39
See all 39 papersRelatives10
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE OCI-AML-2-CopGFP | CVCL_F6C9 | Cell lines | |
| Derived from it | EDITGENE OCI-AML-2-FLUC | CVCL_F5US | Cell lines | |
| Derived from it | OU-AML-1 | CVCL_8391 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-2 | CVCL_8392 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-3 | CVCL_8393 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-4 | CVCL_8394 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-5 | CVCL_8395 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-6 | CVCL_8396 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-7 | CVCL_8397 | Has a recorded problem | Cell lines |
| Derived from it | OU-AML-8 | CVCL_8398 | Has a recorded problem | Cell lines |
Cell banks4
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1619
GET https://conductscience.org/api/cell-lines/v1/CVCL_1619/papers?page=2